Study found Epilepsy drug effective for osteoarthritis – A study conducted by Yale researchers has identified a drug target that may alleviate joint degeneration associated with osteoarthritis (OA), a debilitating condition that affects millions of people worldwide. The study found that drugs targeting a specific sodium channel, Nav1.7, could potentially slow joint degeneration in OA patients. Key findings from the study include:

The researchers deleted Nav1.7 genes from collagen-producing cells and significantly reduced joint degeneration in mouse models of OA.

Drugs used to block Nav1.7, such as carbamazepine, a sodium channel blocker currently used to treat epilepsy and trigeminal neuralgia, also provided benefits in preventing cartilage destruction.

The same Nav1.7 channels are present in non-excitable cells that produce extracellular matrix components, which are essential for maintaining joint health.

The study suggests that the same Nav1.7 channels that play a role in pain signaling in the nervous system may also contribute to joint degeneration in OA.

By targeting these channels, researchers hope to develop new therapies for OA treatment. However, further validation is needed before these drugs can be repurposed for OA treatment in humans.

Are there any other drugs that have been repurposed for treating osteoarthritis?

Several drugs have been repurposed for treating osteoarthritis (OA) due to their potential to alleviate pain, inflammation, and joint degeneration. Some of these drugs include:
Atorvastatin: This drug is a vascular anti-inflammatory that has shown promise in treating OA.

Low molecular weight heparin: Another vascular anti-inflammatory, low molecular weight heparin has been considered for OA treatment.

Aldosterone: This hormone has been investigated for its potential role in OA treatment.

Talarozole: This drug may help boost levels of retinoic acid in the body, which has been shown to suppress inflammation and promote joint health.

These repurposed drugs have the potential to improve OA symptoms and slow disease progression. However, it is essential to note that more research and clinical trials are needed to confirm their effectiveness and safety in treating OA. Study source 

ALSO READ: Wearing Hearing Aids Linked to Longer Life – Study

Content source – www.soundhealthandlastingwealth.com